We conducted a randomized clinical trial to test a mobile health behavioral intervention designed to enhance HIV treatment as prevention (B-TasP) by simultaneously increasing combination antiretroviral therapies (cART) adherence and improving the sexual health of people living with HIV.
A cohort of sexually active men (n = 383) and women (n = 117) living with HIV were enrolled. Participants were baseline assessed and randomized to either (1) B-TasP adherence and sexual health intervention or (2) general health control intervention. Outcome measures included HIV RNA viral load, cART adherence monitored by unannounced pill counts, indicators of genital tract inflammation, and sexual behaviors assessed over 12 months.
Eighty-six percent of the cohort was retained for 12-month follow-up. The B-TasP intervention demonstrated significantly lower HIV RNA, OR = 0.56, P = 0.01, greater cART adherence, Wald χ2 = 33.9, P = 0.01, and fewer indicators of genital tract inflammation, Wald χ2 = 9.36, P = 0.05, over the follow-up period. Changes in sexual behavior varied, with the B-TasP intervention showing lower rates of substance use in sexual contexts, but higher rates of condomless sex with non-HIV positive partners occurred in the context of significantly greater beliefs that cART reduces HIV transmission.
Theory-based mobile health behavioral interventions can simultaneously improve cART adherence and sexual health in people living with HIV. Programs aimed to eliminate HIV transmission by reducing HIV infectiousness should be bundled with behavioral interventions to maximize their impact and increase their chances of success.
*Institute for Collaboration on Health, Intervention, and Policy, University of Connecticut, Storrs, CT; and
†Department of Pediatrics, Center for AIDS Research, Emory University School of Medicine, Atlanta, GA.
Correspondence to: Seth C. Kalichman, PhD, Institute for Collaboration on Health, Intervention, and Policy, University of Connecticut, 2006 Hillside Road, Storrs, CT 06269 (e-mail: firstname.lastname@example.org).
Supported by Grants from the National Institute on Drug Abuse (NIDA) R01-DA033067 (S.C.K.) and National Institute of Allergy and Infectious Diseases P30-AI050409 (R.F.S.).
The authors have no conflicts of interest to disclose.
Received September 07, 2017
Accepted January 18, 2018